1. Search Result
Search Result
Results for "

antihyperglycemic

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

16

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-121811

    Lanceolatin C

    Glucosidase Metabolic Disease Inflammation/Immunology
    Pongamol (Lanceolatin C) is potent α-glucosidase inhibitor (IC50=103.5 μM) and has free-radical (DPPH) scavenging,antihyperglycemic, and antihyperglycemic activities .
    Pongamol
  • HY-B0089
    Acarbose
    3 Publications Verification

    BAY g 5421

    Glucosidase Metabolic Disease
    Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .
    Acarbose
  • HY-N0669
    Stevioside
    2 Publications Verification

    Apoptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Stevioside is an orally active sweetener that can be isolated from Stevia rebaudiana, with antihypertensive, antihyperglycemic, antioxidant, anti-inflammatory and anti-tumor activities .
    Stevioside
  • HY-146128

    Glucosidase Metabolic Disease
    Anti-hyperglycemic agent-1 (compound 10) is a potent α-Glucosidase inhibitor, with an IC50 of 0.53 μM. Anti-hyperglycemic agent-1 can be used for diabetes research .
    <em>Anti-hyperglycemic</em> agent-1
  • HY-131488

    Others Metabolic Disease
    8-Debenzoylpaeoniflorin, a monoterpene glycoside, is a natural product that could be isolated from the dried root of Paeonia lactiflora Pall. 8-Debenzoylpaeoniflorin has antihyperglycemic activity .
    8-Debenzoylpaeoniflorin
  • HY-14291
    Vildagliptin
    4 Publications Verification

    LAF237; NVP-LAF 237

    Dipeptidyl Peptidase Ferroptosis Apoptosis Metabolic Disease
    Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .
    Vildagliptin
  • HY-14291A

    LAF237 dihydrate; NVP-LAF 237 dihydrate

    Dipeptidyl Peptidase Ferroptosis Apoptosis Metabolic Disease
    Vildagliptin dihydrate (LAF237 dihydrate) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin dihydrate possesses excellent oral bioavailability and potent antihyperglycemic activity .
    Vildagliptin dihydrate
  • HY-14291B

    (2R)-LAF237; (2R)-NVP-LAF 237

    Others Metabolic Disease
    (2R)-Vildagliptin is the isomer of Vildagliptin (HY-14291), and can be used as an experimental control. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .
    (2R)-Vildagliptin
  • HY-12608

    JNJ-39933673

    SGLT Metabolic Disease
    TA-1887 (JNJ-39933673) is a highly potent, selective and orally active SGLT2 inhibitor (IC50: 1.4 nM) with antihyperglycemic effects. TA-1887 can be used in the research of diabetes .
    TA-1887
  • HY-109500

    meso-Nordihydroguaiaretic acid; meso-NDGA

    Lipoxygenase Metabolic Disease
    Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally active lipoxygenase inhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential for the research of type II diabetes .
    Masoprocol
  • HY-14860
    1-Deoxynojirimycin
    3 Publications Verification

    Duvoglustat

    Glucosidase PI3K Metabolic Disease
    1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .
    1-Deoxynojirimycin
  • HY-14860A
    1-Deoxynojirimycin hydrochloride
    3 Publications Verification

    Duvoglustat hydrochloride

    Glucosidase PI3K Bacterial Antibiotic Infection Metabolic Disease
    1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin hydrochloride possesses antihyperglycemic, anti-obesity, and antiviral features .
    1-Deoxynojirimycin hydrochloride
  • HY-157390

    Dipeptidyl Peptidase Metabolic Disease
    DPP-4-IN-9 (compound 6l) is a potent inhibitor of dipeptidyl peptidase DPP-4 (IC50: 8.22 nM). DPP-4-IN-9 has antihyperglycemic activity .
    DPP-4-IN-9
  • HY-14291S2

    LAF237-13C5,15N; NVP-LAF 237-13C5,15N

    Isotope-Labeled Compounds Metabolic Disease
    Vildagliptin- 13C5, 15N (LAF237- 13C5, 15N; NVP-LAF 237- 13C5, 15N) is a 13C- and 15N-labeled Vildagliptin (HY-14291). Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .
    Vildagliptin-13C5,15N
  • HY-12611

    GW-869682X

    SGLT Metabolic Disease
    Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes .
    Sergliflozin etabonate
  • HY-100428

    MCC-555; Isaglitazone

    Netoglitazone is a dual agonist of PPARα and PPARγ with antihyperglycemic activity .
    Netoglitazone
  • HY-N0807

    Others Metabolic Disease Cancer
    Swertiamarin, a secoiridoid glycoside found in genera of Enicostemma littorale, confers anti-hyperglycemic and anti-hyperlipidemic effects .
    Swertiamarin
  • HY-N0547

    Others Metabolic Disease
    Nomilin is a limonoid compound obtained from the extracts of citrus fruits. Nomilin is an anti-obesity and anti-hyperglycemic agent .
    Nomilin
  • HY-101782

    SGLT Metabolic Disease
    HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC50 of 1.3 nM. Antihyperglycemic activities .
    HSK0935
  • HY-N0472
    Geraniin
    2 Publications Verification

    TNF Receptor Metabolic Disease Inflammation/Immunology Cancer
    Geraniin is a TNF-α releasing inhibitor with numerous activities including anticancer, anti-inflammatory, and anti-hyperglycemic activities, with an IC50 of 43 μM.
    Geraniin
  • HY-A0176

    Glisoxepide, a sulphonamide derivative, is an orally available nonselective K(ATP) channel blocker, with antihyperglycemic activity and cardiovascular regulation effect .
    Glisoxepide
  • HY-133127A

    Glucokinase Metabolic Disease
    AR453588 hydrochloride is a potent and orally bioavailable anti-diabetic glucokinase activator, with an EC50 of 42 nM. AR453588 hydrochloride shows anti-hyperglycemic activity .
    AR453588 hydrochloride
  • HY-133127

    Glucokinase Metabolic Disease
    AR453588 is a potent and orally bioavailable anti-diabetic glucokinase activator, with an EC50 of 42 nM. AR453588 shows anti-hyperglycemic activity .
    AR453588
  • HY-N1185

    Tagitinin A is a sesquiterpene with anti-hyperglycemic activity. Tagitinin A significantly inhibits glucose uptake in differentiated 3T3-L1 adipocytes .
    Tagitinin A
  • HY-N10362

    Dipeptidyl Peptidase Metabolic Disease
    Ellipyrone B, an antihyperglycemic γ-pyrone enclosed macrocyclic polyketide, shows inhibition potential against dipeptidyl peptidase-4 (IC50=0.48 mM) .
    Ellipyrone B
  • HY-N0336A

    (Z)-Butylidenephthalide

    (Z)-3-Butylidenephthalide is an antihyperglycemic agent by inhibiting the activity of intestinal and yeast R-glucosidases (IC50=2.35 mM; Ki=4.86 mM) .
    (Z)-3-Butylidenephthalide
  • HY-N8018

    PKC Glucosidase Angiotensin-converting Enzyme (ACE) Neurological Disease Metabolic Disease
    Leucosceptoside A is a phenylethanoid glycoside with anti-hyperglycemic and anti-hypertensive activities. Leucosceptoside A shows inhibitory activity against α-glucosidase and PKCα (IC50 of 19.0 μM) .
    Leucosceptoside A
  • HY-B0089A

    Bay-g 5421 sulfate

    Glucosidase Metabolic Disease
    Acarbose (BAY g 5421) sulfate, antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose sulfate can potentiate the hypoglycemic effects of sulfonylureas or insulin .
    Acarbose sulfate
  • HY-110118

    PPAR
    Edaglitazone is a potent, selective and orally active PPARγ agonist, with EC50s of 35.6 nM and 1053 nM for PPARα and PPARγ, respectively. Edaglitazone displays antiplatelet, antidiabetic and anti-hyperglycemic activity .
    Edaglitazone
  • HY-N1390

    Syringaldehyde is a polyphenolic compound belonging to the group of flavonoids and is found in different plant species like Manihot esculenta and Magnolia officinalis . Syringaldehyde moderately inhibits COX-2 activity with an IC50 of 3.5 μg/mL . Anti-hyperglycemic and anti-inflammatory activities .
    Syringaldehyde
  • HY-14291S1

    LAF237-d7; NVP-LAF 237-d7

    Isotope-Labeled Compounds Dipeptidyl Peptidase Ferroptosis Apoptosis Metabolic Disease
    Vildagliptin-d7 is deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1].
    Vildagliptin-d7
  • HY-14291S

    LAF237-d3; NVP-LAF 237-d3

    Isotope-Labeled Compounds Dipeptidyl Peptidase Ferroptosis Apoptosis Metabolic Disease
    Vildagliptin-d3 is the deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1][2].
    Vildagliptin-d3
  • HY-W068771

    Endogenous Metabolite Neurological Disease Metabolic Disease
    (E)-3-(4-Methoxyphenyl)acrylic acid (compound 3) is isolated from Arachis hypogaea, Scrophularia buergeriana Miquel, Aquilegia vulgaris, Anigozanthos preissii and so on. (E)-3-(4-Methoxyphenyl)acrylic acid shows significant hepatoprotective activity, anti-amnesic, cognition-enhancing activity, antihyperglycemic, and neuroprotective activities .
    (E)-3-(4-Methoxyphenyl)acrylic acid
  • HY-156380

    Amylases Glucosidase Metabolic Disease
    α-Amylase/α-Glucosidase-IN-6 (compound 5j) is a potent dual inhibitor of α-amylase and α-glucosidase, with IC50s of 17.0 and 40.1 µM, respectively. α-Amylase/α-Glucosidase-IN-6 exhibits anti-hyperglycemic activities .
    α-Amylase/α-Glucosidase-IN-6
  • HY-16482

    Endogenous Metabolite Neurological Disease Metabolic Disease
    Teglicar is a selective and reversible orally active liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1) inhibitor with an IC50 value of 0.68 μM and a Ki value of 0.36 μM. Teglicar has a potential antihyperglycemic propert. Teglicar can be used for the research of diabetes and neurodegenerative disease including Huntington's disease (HD) .
    Teglicar
  • HY-131334

    AMPK Metabolic Disease
    AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect .
    AMPK activator 4
  • HY-108615

    GPi 819

    Others Endocrinology
    CP 316819 is a potent glycogen phosphorylase (GPase) inhibitor with antihyperglycemic effect (IC50 values are 17 and 34 nM against human skeletal muscle glycogen phosphorylase (huSMGPa) and liver glycogen phosphorylase (huLGPa) respectively).CP 316819 causes glycogen accumulation under normoglycemic conditions but permits glycogen utilization when glucose concentrations are low.CP-316819 prevents neuronal cell death and maintains brain electrical currents .
    CP-316819
  • HY-15675

    Glucokinase Metabolic Disease
    AZD1656 is a potent, selective and orally active glucokinase activator with an EC50 of 60 nM. AZD1656 has the potential for type 2 diabetes research .
    AZD1656
  • HY-N6660

    Tricaprin; Glyceryl tridecanoate

    Endogenous Metabolite Androgen Receptor Metabolic Disease
    Trisdecanoin (Tricaprin; Glyceryl tridecanoate) is an orally available precursor of decanoic acid (DA precursor) that can be hydrolyzed to decanoic acid. Trisdecanoin and its metabolite capric acid not only provide the body with a quick source of energy, but can also affect lipid metabolism. Trisdecanoin is a major component of medium chain triglycerides (MCT), which has preventive or inhibitory properties for abdominal aortic aneurysms (AAA), inhibition of cardiovascular disease, and anti-androgen (NSAA) and anti-hyperglycemic properties. Trisdecanoin can be used as an additive in food, medicine and cosmetics .
    Trisdecanoin
  • HY-17386
    Rosiglitazone
    Maximum Cited Publications
    84 Publications Verification

    BRL 49653

    PPAR TRP Channel Autophagy Ferroptosis Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer .
    Rosiglitazone
  • HY-17386B

    BRL 49653 potassium

    PPAR TRP Channel Autophagy Apoptosis Ferroptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Rosiglitazone (BRL 49653) potassium is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone potassium is a TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone potassium can be used in the research of obesity and diabetes, senescence, ovarian cancer .
    Rosiglitazone potassium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: